Chemistry:Combretastatin A-4 phosphate
 | |
| Clinical data | |
|---|---|
| Other names | CA4P; CA4PD; fosbretabulin; fosbretabulin disodium |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H21O8P |
| Molar mass | 396.332 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Combretastatin A-4 phosphate (fosbretabulin, and its salt fosbretabulin disodium) is a microtubule destabilising drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumours causing central necrosis. It is a derivative of combretastatin.
Combretastatin A-4 phosphate (CA4P) is a prodrug. In vivo, it is dephosphorylated to its active metabolite, combretastatin A-4.[1]
CA4P is also known as Fosbretabulin Tromethamine.[2]
In July 2007 the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of CA-4-P in combination with carboplatin for the treatment of anaplastic thyroid cancer.[3] There is currently no fully FDA approved treatment for this form of cancer.
By 2017 it had completed multiple clinical trials (e.g. for solid tumours,[4] non-small cell lung cancer[5]) with more in progress.[6]
See also
- Combretastatin, e.g. for the chemical synthesis
References
- ↑ Combretastatin A-4 phosphate on www.cancer.gov
- ↑ A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers (GI-NETorPNET)
- ↑ Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
- ↑ Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
- ↑ A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer (FALCON)
- ↑ CA4P clinical trials
 |
